CLINICAL RESEARCH: HEART RHYTHM DISORDER
Association Between C-Reactive Protein and Recurrence of Atrial Fibrillation After Successful Electrical CardioversionA Meta-Analysis
Tong Liu, MD, PhD*,
Guangping Li, MD, PhD*,*,
Lijian Li, PhD and
Panagiotis Korantzopoulos, MD, PhD
* Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, People’s Republic of China
College of Graduate Students, Tianjin Medical University, Tianjin, People’s Republic of China
Department of Cardiology, "G. Hatzikosta" General Hospital of Ioannina, Ioannina, Greece.
Manuscript received October 24, 2006;
revised manuscript received December 4, 2006,
accepted December 19, 2006.
* Reprint requests and correspondence: Prof. Guangping Li, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, People’s Republic of China. (Email: gp_limail{at}yahoo.com.cn).
 |
Abstract
|
|---|
Objectives: We conducted a systematic review and meta-analysis of observational studies to examine the association between baseline C-reactive protein (CRP) levels and the recurrence of atrial fibrillation (AF) after successful electrical cardioversion (EC).
Background: Current evidence links AF to the inflammatory state. Inflammatory indexes such as CRP have been related to the development and persistence of AF. However, inconsistent results have been published with regard to the role of CRP in predicting sinus rhythm maintenance after successful EC.
Methods: Using PubMed, the Cochrane clinical trials database, and EMBASE, we searched for literature published June 2006 or earlier. In addition, a manual search was performed using all review articles on this topic, reference lists of papers, and abstracts from conference reports. Of the 225 initially identified studies, 7 prospective observational studies with 420 patients (229 with and 191 without AF relapse) were finally analyzed.
Results: Overall, baseline CRP levels were greater in patients with AF recurrence. The standardized mean difference in the CRP levels between the patients with, and those without AF was 0.35 units (95% confidence interval 0.01 to 0.69); test for overall effect z-score = 2.00 (p = 0.05). The heterogeneity test showed that there were significant differences between individual studies (p = 0.02; I2 = 60.2%). Further analysis revealed that differences between the CRP assays possibly account for this heterogeneity.
Conclusions: Our meta-analysis suggests that increased CRP levels are associated with greater risk of AF recurrence, although there was significant heterogeneity across the studies. The use of CRP levels in predicting sinus rhythm maintenance appears promising but requires further study.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | CRP = C-reactive protein | | EC = electrical cardioversion | | ELISA = enzyme-linked immunosorbent assay |
|
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and its prevalence has increased during the past few decades (1,2). Because AF is independently associated with increased cardiovascular mor-bidity and mortality, it unequivocally represents a major public health problem (1,2). Although control of the ventricular response is an acceptable treatment in certain subgroups of patients, restoration and maintenance of sinus rhythm remains the preferred strategy in many patients (2,3). This strategy offers several potential benefits, such as the prevention of electrical and structural remodeling of the atria, improved hemodynamic function, amelioration of symptoms, and improvement in the quality of life (3,4). Although some recent studies indicate increased efficacy of pharmacological cardioversion using combination therapy (5,6), electrical cardioversion (EC) is the most commonly used method for sinus rhythm restoration in patients with persistent AF.
Despite the use of antiarrhythmic agents for sinus rhythm maintenance, a considerable proportion of patients relapse to AF (1,2). It is generally believed that these relapses are associated with older age, atrial dilation, and long duration of the arrhythmia. This tendency to become sustained over time cannot be easily managed, representing a challenging therapeutic problem. An increasing body of evidence suggests the role of inflammation in the genesis and perpetuation of AF (7–10). The possibility that the association of inflammation with AF could be examined with the use of C-reactive protein (CRP) has captured the attention of many researchers (11). In the past few years, several studies have investigated the association between baseline CRP levels and AF recurrence rates after successful EC. Although some of these studies indicated a positive association between CRP levels and AF recurrence (12–15), others failed to demonstrate such a relationship (16–18). Therefore, we conducted a systematic review of the evidence obtained from observational studies to evaluate the association between CRP levels before cardioversion and AF recurrence rates after successful EC.
|
Methods
|
|---|
Meta-analyses of observational studies present particular challenges because of inherent biases and differences in study designs. Consequently, we performed this analysis according to the guidelines of the Meta-analysis of Observational Studies in Epidemiology Group (MOOSE) (19).
Inclusion criteria.
Studies were considered eligible for this review if they met the following criteria: 1) they were of a prospective observational study design; 2) they evaluated the potential association between CRP levels before cardioversion and AF recurrence after successful EC; 3) they used AF recurrence rates as an outcome; and 4) the period of follow-up was no shorter than 1 week. We included published and unpublished studies without language restriction.
Search strategies.
We carefully searched MEDLINE (January 1966 to June 2006), EMBASE (January 1980 to June 2006), and the Cochrane Controlled Trials Register (Cochrane Library Issue 2, 2006) databases to identify relevant studies. We used the following keywords: "C-reactive protein," "inflammation," and "atrial fibrillation." Titles and abstracts as well as the reference lists of all of the identified reports were examined independently by 2 reviewers (T.L. and L.L.) to include potentially relevant studies. The 2 reviewers agreed on the inclusion/exclusion status in 92% of the reviewed studies. Disagreements were resolved by discussion or consensus of a third reviewer (G.L.). Additionally, a manual search was conducted using all review articles on this topic, bibliographies of original papers, and abstracts of the scientific sessions of the American College of Cardiology, the American Heart Association, the European Society of Cardiology, and the North American Society of Pacing and Electrophysiology (Heart Rhythm Society) during the past 5 years.
Quality assessment and data extraction.
Because quality scoring is controversial in meta-analyses of observational studies, we systematically assessed several key points of study quality. Two reviewers (T.L. and L.L.) independently appraised each article included in our analysis according to a critical review checklist of the Dutch Cochrane Centre which was proposed by MOOSE (19). The key points of this checklist are as follows: 1) clear definition of study population; 2) clear definition of outcomes and outcome assessment; 3) independent assessment of outcome parameters; 4) sufficient duration of follow-up; 5) no selective loss during follow-up; and 6) important confounders and prognostic factors identified. If a study did not clearly mention one of these key points, we considered that it had not been performed and, consequently, that there was a possibility for underestimation of the reported characteristics.
Two blinded reviewers (T.L. and L.L.) independently performed data extraction using a standard data extraction form to determine eligibility for inclusion and extract data. The extracted data elements of this review included: 1) publication details: first author’s last name, publication year, and origin of the studied population; 2) study design; 3) characteristics of the studied population: sample size, age, gender, diagnoses, methods of CRP measurement, duration of follow-up, number of withdrawals, and dropouts; 4) end point evaluation (methods of AF detection); 5) rates of AF recurrence and sinus rhythm maintenance during the follow-up period, and means and SDs of CRP in each group. Disagreements were resolved by consensus with a third reviewer (G.L.).
If the study provided medians and interquartile ranges instead of means and SDs, we imputed the means and SDs as described by Hozo et al. (20). We calculated the lower and upper ends of the range by multiplying the difference between the median and upper and lower ends of the interquartile range by 2 and adding or subtracting the product from the median, respectively.
Statistical analysis.
To accommodate differences in the way in which CRP measured and reported across various laboratories, the absolute CRP levels were converted into a common unit by calculating standardized effect sizes. Standardized effect sizes were derived by dividing the mean difference of CRP levels in AF recurrence and no AF recurrence groups of each study by its SD. We used the I2 statistic to measure the extent of inconsistency among the results and tested the heterogeneity using Cochran’s Q test. Because this test has poor power in the case of few studies, we considered both the presence of significant heterogeneity at the 10% level of significance and values of I2 exceeding 56% as an indicator of significant heterogeneity (21), so a pooled effect was calculated with a random-effects model which was used to take into account within-study and between-study variance, otherwise, with a fixed-effects model. To explore sources of heterogeneity, we performed several sensitivity and subgroup analyses. Publication bias was evaluated using the funnel plot. All analyses were conducted using Review Manager version 4.2 (Revman, The Cochrane Collaboration, Oxford, United Kingdom).
|
Results
|
|---|
Two hundred twenty-five records were identified by the primary literature search. However, after screening the titles and abstracts, 194 studies were excluded because they were either laboratory studies, review articles, or irrelevant to the current analysis. Of the 31 reports selected for detailed evaluation, 17 studies did not assess the AF patients who underwent EC, 2 studies were randomized control trials that evaluated drug interventions on AF prevention after successful EC (22,23), and 2 further studies were excluded because they were preliminary abstracts followed by subsequent full manuscripts. One study was excluded because a portion of the studied patients followed after unsuccessful EC (24), whereas in another one the follow-up period was too short (25). Finally, in one additional study, CRP levels were not reported in the AF recurrence group (26). Consequently, 7 prospective observational cohort studies (12–18) finally were included in our meta-analysis (Fig. 1). Overall, there were 420 patients involved in our review: 229 in the AF recurrence group, and 191 in the no AF recurrence group. The follow-up period varied between 7 and 140 days. The quality assessment of the 7 studies is presented in Table 1, whereas the characteristics of each study are depicted in Table 2.
Four studies showed that patients with AF recurrence had greater CRP levels than those without (12–15), whereas CRP levels did not show significant difference between the 2 groups in 3 other studies (16–18). Overall, CRP concentration was greater in patients with AF recurrence. The standardized mean difference in the CRP levels between the patients with, and those without AF recurrence was 0.35 units (95% confidence interval 0.01 to 0.69) (Fig. 2), and the z-score for overall effect was 2.00 (p = 0.05). The heterogeneity test showed that there were significant differences between individual studies (p = 0.02; I2 = 60.2%). We subsequently performed sensitivity and subgroup analyses to find the origin of this heterogeneity. After removing 1 study that enrolled patients with atrial flutter or 1 study that had the shortest follow-up period, the analysis did not find a significant influence on the results. Of note, after excluding the study by Zarauza et al. (15), which used a high-sensitivity C-reactive protein enzyme-linked immunosorbent assay (ELISA) to measure CRP levels, heterogeneity test showed that there were no significant differences between the remaining 6 studies (p = 0.32; I2 = 14.1%), whereas the standardised mean difference in the CRP levels between the patients with and without AF recurrence was 0.23 units (95% CI 0.02 to 0.45); the z-score for overall effect was 2.11 (p = 0.03). Therefore, differences in the CRP assay may be a possible source of heterogeneity.
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Comparison of CRP Levels Between AF Recurrence and No AF Recurrence Groups in the 7 Included Studies
AF = atrial fibrillation; CI = confidence interval; CRP = C-reactive protein; SMD = standardized mean difference.
|
|
In addition, we performed a prespecified subgroup analysis of studies with a follow-up period of at least 2 months and those of <2 months. The proportion of total variation across studies that was due to heterogeneity rather than chance was I2 = 58.4% (p = 0.09) in the 3 studies with a follow-up period of at least 2 months, and I2 = 69.5% (p = 0.02) in the 4 studies with a follow-up period of <2 months. Thus, it did not explain the cause of heterogeneity in our results. The funnel plot (Fig. 3) suggested that there was little publication bias, although the small number of studies made it difficult to interpret.
View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Funnel Plot of the Meta-Analysis
Review: C-reactive protein and recurrence of AF after successful electrical cardioversion. Comparison: 01 AF recurrence versus no AF recurrence. Outcome: 01 AF recurrence. SE = standard error; other abbreviations as in Figure 2.
|
|
|
Discussion
|
|---|
In this meta-analysis of 7 prospective observational studies, we demonstrated that increased baseline CRP levels are associated with greater risk for AF recurrence after successful external EC, although there was significant heterogeneity across the studies. After excluding a study that caused heterogeneity (15), the overall effect of CRP elevation on AF relapse was more prominent (z-score = 2.11, p = 0.03). Keeping in mind the clinical importance of sinus rhythm maintenance after successful EC, as well as the inconsistent published results regarding the effect of inflammation in this setting, this meta-analysis is of special importance.
The pathophysiological mechanism that underlies the development of electrophysiological and structural substrate that promotes AF maintenance and recurrence has been named "atrial remodelling" (27). Currently, there is an increasing research interest on the role of inflammation and oxidative stress in the pathophysiology of AF (7–11,28). It has also been speculated that these processes are interrelated and contribute to the atrial remodeling (7,9,10,28). Remarkably, an increasing body of evidence links AF to the inflammatory state (9,10). Inflammatory indexes, mainly CRP, have been related to future AF development, AF recurrences after cardioversion, and to the associated prothrombotic state (9,10). Moreover, the persistence of AF has been associated with the degree of inflammation (29). Also, several pharmacological approaches with nonchannel blocking drugs that, among other pleiotropic, have anti-inflammatory properties, show favorable effects on AF (10,22,28,30,31). These include inhibitors of the renin-angiotensin system, statins, dietary antioxidants, corticosteroids, n-3 fatty acids, and others (10,22,28,30,31). Dernellis and Panaretou (32) indicated the efficacy of corticosteroid treatment in preventing recurrent AF but, more interestingly, they demonstrated that corticosteroid treatment significantly reduced the CRP levels from the first month, whereas a strong relationship between CRP increase and the risk of AF recurrence was observed (32).
Despite the aforementioned evidence, it is not yet clear whether inflammation is a primary pathogenetic event or a consequence of AF. However, there is a possibility that both processes feeding each other leading to a vicious cycle. It could be hypothesized that ongoing inflammation can enhance atrial remodeling, thus promoting AF recurrence (13). This hypothesis is supported by the temporal relation of increases in inflammatory indexes (CRP, complement, white blood cell count) after cardiac surgery and the onset of postoperative AF (33,34). Moreover, elevated CRP levels have been reported very early (even in the first 24 h) after AF initiation, suggesting that inflammation may promote AF persistence (29). Very recently, it was demonstrated that in patients with acute myocardial infarction there seems to be an independent positive association between elevated CRP and new-onset AF suggesting a pathogenetic role for inflammation (35,36).
However, if inflammation simply accompanies atrial remodeling, then the restoration of sinus rhythm might lead to the gradual decrease of the inflammatory markers, whereas failure of the reverse atrial remodeling and the impeding recurrence of the arrhythmia might be indicated by the abolishment of this decrease. Of note, some investigators claim that the abnormal inflammatory state may be related, at least in part, to other comorbidities. Regardless of the presence or not of a causal relationship, the study of baseline CRP levels and/or their variation after cardioversion may provide significant prognostic information regarding sinus rhythm maintenance (16,37). C-reactive protein is an acute-phase protein that has been emerged as a reliable biomarker of systemic inflammation in several cardiovascular diseases (11,38). Importantly, CRP is an easily determined marker in everyday clinical practice worldwide and thus, successive measurements can be easily performed.
Undoubtedly, a unique basal measurement of CRP before AF cardioversion cannot reflect the inflammatory process throughout time. To date, only 1 small study examined the time-course of the inflammatory indexes after cardioversion (16). In this study, serial measurements of CRP, fibrinogen, and white blood cell count were performed on the first, third, and seventh day after cardioversion. It was demonstrated that fibrinogen levels increased significantly in patients who relapsed to AF but remained stable in patients who remained in sinus rhythm. In the latter patients, CRP values tended to decrease after cardioversion, but white blood cell count was significantly lower on the seventh day compared with baseline values (16). It could be therefore speculated that the variation of inflammatory indexes after EC of persistent AF might have prognostic implications (16). Moreover, successive measurement of simple inflammatory indexes might be clinically useful in monitoring the effectiveness of various anti-inflammatory treatments in patients with AF (16). In 2 further studies, CRP levels were determined only once after cardioversion. Cosgrave et al. (17) measured CRP at baseline and 8 weeks after cardioversion and found no differences in patients who recurred to AF as well as in those who remained in sinus rhythm. Similar results also were obtained by Buob et al. (18) by measuring CRP at baseline and 1 month after EC.
In our analysis, we included 1 study that had a short follow-up period of just 1 week (16). We consider that this time interval is sufficient and critical because the greatest incidence of AF recurrence occurs during the first days after cardioversion. Tieleman et al. (39) have demonstrated that the recurrence rate can reach the level of 35% in the first 5 days after cardioversion. It also has been suggested that atrial electrical remodeling resolves during the first days after cardioversion of persistent AF and may be related to early recurrence rates (39). In addition, as already mentioned, the removal of this study from the analysis did not have a significant impact on the results.
When between-study variation cannot be explained by chance, exploration of the reasons for heterogeneity rather than derivation of a single summary estimate have been emerged as the main goal of a meta-analysis (40). The heterogeneity test of our analysis showed that there were significant differences between individual studies. Subsequently, sensitivity and subgroup analyses were performed to investigate the underlying causes; differences between the measurements of CRP in the studies may be a possible source of heterogeneity. In the aforementioned 7 studies, in 6 of them (12–14,16–18) researchers used immunonephelometric assay to measure CRP concentrations, and only in 1 study (15) did researchers assess CRP by using ELISA. The ELISA methodology is used primarily for research purposes and is not ideal for routine use in highly automated clinical laboratories (41). Recently, latex-enhanced immunonephelometric method and the immunoturbidimetric assay have been evaluated and validated clinically (42). These assays possess improved sensitivity and precision at low concentrations of CRP. Finally, we demonstrated that enrolment of patients with atrial flutter and short follow-up duration did not explain the aforementioned heterogeneity.
Study limitations.
We feel that our study adds to the current understanding of the association between inflammation and AF recurrence. However, some potential limitations may be apparent. Firstly, our analysis is based on observational studies and may be subjected to the potential biases of such studies. Therefore, our results should be interpreted cautiously. Second, converting non-normally distributed statistics (median and range) to normally distributed statistics (mean and SD) may be a cause of bias in our analysis. Third, because the number of studies in our meta-analysis was small, we cannot exclude the possibility of publication bias, although our funnel plot showed that publication bias is unlikely, (43). Fourth, although most of the studies attempted to control the potential confounders, the degree to which this was accomplished varied among them. Fifth, no study of those included in the meta-analysis provided information regarding the inflammatory state before the beginning of AF. Finally, methods of AF detection were different between the trials and therefore some asymptomatic episodes of AF may be overlooked.
|
Conclusions
|
|---|
In conclusion, our meta-analysis suggests that increased baseline CRP levels are associated with higher risk of AF recurrence after successful EC, although there was a significant heterogeneity across the studies. Our results need to be confirmed by larger well-designed randomized studies with longer follow-up periods. The merit of successive measurement of CRP after cardioversion, as well as the examination of the role of other inflammatory markers such as white blood cell count, and interleukin-6, constitutes a subject for future research.
|
References
|
|---|
1. Nattel S. New ideas about atrial fibrillation 50 years on Nature 2002;415:219-226.[CrossRef][Medline]2. Korantzopoulos P, Kolettis TM, Goudevenos JA, Siogas K. Errors and pitfalls in the non-invasive management of atrial fibrillation Int J Cardiol 2005;104:125-130.[CrossRef][Web of Science][Medline] 3. Van Gelder IC, Hemels MEW. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm Europace 2006;8:943-949.[Abstract/Free Full Text] 4. Chung MK. Randomized trials of rate vs rhythm control for atrial fibrillation J Interv Card Electrophysiol 2004;10:43-53. 5. Hongo RH, Themistoklakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents J Am Coll Cardiol 2004;44:864-868.[Abstract/Free Full Text] 6. Korantzopoulos P, Kolettis TM, Papathanasiou A, et al. Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation Heart 2006;92:631-634.[Abstract/Free Full Text] 7. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress Med Sci Monit 2003;9:RA225-RA229.[Medline] 8. Liu T, Li G. Is atrial fibrillation an inflammatory disease? Med Hypotheses 2005;64:1237-1238.[CrossRef][Web of Science][Medline] 9. Engelmann MDM, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation Eur Heart J 2005;26:2083-2092.[Abstract/Free Full Text] 10. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-149.[Abstract/Free Full Text] 11. Madrid AH. C-reactive protein and atrial fibrillationAn old marker looking for a new target. Rev Esp Cardiol 2006;59:94-98.[CrossRef][Web of Science][Medline] 12. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion Heart 2005;91:1303-1305.[Abstract/Free Full Text] 13. Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion J Am Coll Cardiol 2005;46:1284-1287.[Abstract/Free Full Text] 14. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion Int J Cardiol 2006;108:346-353.[CrossRef][Web of Science][Medline] 15. Zarauza J, Rodriguez Lera MJ, Farinas Alvarez C, et al. Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion Rev Esp Cardiol 2006;59:125-129.[CrossRef][Web of Science][Medline] 16. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillationIs there an association with early recurrence rates?. Int J Clin Pract 2005;59:881-885.[CrossRef][Web of Science][Medline] 17. Cosgrave J, Foley JB, Bahadur K, Bennett K, Crean P, Walsh MJ. Inflammatory markers are not associated with outcomes following elective external cardioversion Int J Cardiol 2006;110:373-377.[CrossRef][Web of Science][Medline] 18. Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation Pacing Clin Electrophysiol 2006;29:559-563.[CrossRef][Medline] 19. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group Meta-analysis of observational studies in epidemiology: a proposal for reporting JAMA 2000;283:2008-2012.[Abstract/Free Full Text] 20. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample BMC Med Res Methodol 2005;5:13.[CrossRef][Medline] 21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis Stat Med 2002;21:1539-1558.[CrossRef][Web of Science][Medline] 22. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation Int J Cardiol 2005;102:321-326.[CrossRef][Web of Science][Medline] 23. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion Am J Cardiol 2006;97:1490-1493.[CrossRef][Web of Science][Medline] 24. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation Am J Cardiol 2004;94:508-510.[CrossRef][Web of Science][Medline] 25. Gajek J, Zysko D, Mysiak A, Mazurek W. Activation of generalised inflammatory reaction following electrical cardioversion Kardiol Pol 2004;61:225-231.[Medline] 26. Kallergis EM, Kanoupakis EM, Mavrakis HE, et al. Does restoration of sinus rhythm affect high-sensitivity C-reactive protein levels in patients with persistent atrial fibrillation (abstr)? Heart Rhythm 2006;3(Suppl):S233. 27. Shiroshita-Takeshita A, Bianca BJJM, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers J Interv Card Electrophysiol 2005;13:181-193.[CrossRef][Web of Science][Medline] 28. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation Int J Cardiol 2007;115:135-143.[CrossRef][Web of Science][Medline] 29. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation Circulation 2001;104:2886-2891.[Abstract/Free Full Text] 30. Liu T, Li GP, Huang TG. Anti-inflammatory therapies in atrial fibrillation Int J Cardiol 2005;104:359-360.[CrossRef][Web of Science][Medline] 31. Dorian P. The future of atrial fibrillation therapy J Cardiovasc Electrophysiol 2006;17:S11-S16.[CrossRef][Web of Science][Medline] 32. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation Eur Heart J 2004;25:1100-1107.[Abstract/Free Full Text] 33. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia Circulation 1997;96:3542-3548.[Abstract/Free Full Text] 34. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation Am J Cardiol 2004;93:1176-1178.[CrossRef][Web of Science][Medline] 35. Suleiman M, Boulos M, Hammerman H, et al. Elevated levels of C-reactive protein are associated with new onset atrial fibrillation in patients with acute myocardial infarction Eur Heart J 2006;27(Suppl):44(abstr). 36. Patane S, Saviolo R, Patane F, Marte F, Pugliatti P. Inflammation, atrial fibrillation, and acute myocardial infarction Eur Heart J 2006;27(Suppl):47(abstr). 37. Boos CJ, Lip GYH. The role of inflammation in atrial fibrillation Int J Clin Pract 2005;59:870-872.[CrossRef][Web of Science][Medline] 38. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance Curr Probl Cardiol 2004;29:439-493.[Web of Science][Medline] 39. Tieleman RG, Van Gelder IC, Crijns HJGM, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998;31:167-173.[Abstract/Free Full Text] 40. Petitti DB. Approaches to heterogeneity in meta-analysis Stat Med 2001;20:3625-3633.[CrossRef][Web of Science][Medline] 41. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applicationsPart 2. Clin Chem 2001;47:418-425.[Abstract/Free Full Text] 42. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin Chem 1999;45:2136-2141.[Abstract/Free Full Text] 43. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test BMJ 1997;315:629-634.[Abstract/Free Full Text]
Related Article
-
Atrial Fibrillation and C-Reactive Protein: Searching for Local Inflammation
- Antonio Hernández Madrid and Concepción Moro
J. Am. Coll. Cardiol. 2007 49: 1649-1650.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. J. Wilber
Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late?
J. Am. Coll. Cardiol.,
August 25, 2009;
54(9):
796 - 798.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mazza, M. G. Bendini, M. Cristofori, S. Nardi, M. Leggio, R. De Cristofaro, A. Giordano, L. Cozzari, G. Giordano, and R. Cappato
Baseline apnoea/hypopnoea index and high-sensitivity C-reactive protein for the risk of recurrence of atrial fibrillation after successful electrical cardioversion: a predictive model based upon the multiple effects of significant variables
Europace,
July 1, 2009;
11(7):
902 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Zhang
Atrial fibrillation in mainland China: epidemiology and current management
Heart,
July 1, 2009;
95(13):
1052 - 1055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Girerd, P. Pibarot, D. Fournier, P. Daleau, P. Voisine, G. O'Hara, J.-P. Despres, and P. Mathieu
Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery
Eur. Heart J.,
May 2, 2009;
30(10):
1270 - 1278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Letsas, R. Weber, G. Burkle, C. C. Mihas, J. Minners, D. Kalusche, and T. Arentz
Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation
Europace,
February 1, 2009;
11(2):
158 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kourliouros and A. J. Camm
Does inflammation influence atrial fibrillation recurrence following catheter ablation?
Europace,
February 1, 2009;
11(2):
135 - 137.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip
The impact of statin use on atrial fibrillation
QJM,
November 1, 2008;
101(11):
845 - 861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fauchier, B. Pierre, A. de Labriolle, C. Grimard, N. Zannad, and D. Babuty
Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
J. Am. Coll. Cardiol.,
February 26, 2008;
51(8):
828 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Blangy, N. Sadoul, B. Dousset, A. Radauceanu, R. Fay, E. Aliot, and F. Zannad
Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction
Europace,
September 1, 2007;
9(9):
724 - 729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hernandez Madrid and C. Moro
Atrial Fibrillation and C-Reactive Protein: Searching for Local Inflammation
J. Am. Coll. Cardiol.,
April 17, 2007;
49(15):
1649 - 1650.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods